Luspatercept as a First-Line Treatment for Patients With Lower-Risk MDS

Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.

EP: 1.Case Presentation: A 70-Year-Old Man with Myelodysplastic Syndrome (MDS) and Low ISSP-R

EP: 2.Classification and Risk Stratification of MDS

EP: 3.Available First-Line Treatment Options for MDS

EP: 4.The Importance of Early Frontline Treatment Initiation for Patients With MDS

EP: 5.Treating MDS with Erythropoiesis-Stimulating Agents (ESAs)

EP: 6.Rationale for Treatment of MDS With Luspatercept

EP: 7.Dose Titration of Luspatercept in Patient With MDS

Now Viewing

EP: 8.Luspatercept as a First-Line Treatment for Patients With Lower-Risk MDS

EP: 9.Unmet Needs in the Treatment of Patients With MDS

Related Videos